BT 200
Alternative Names: BT-200Latest Information Update: 04 Mar 2025
At a glance
- Originator Band Therapeutics
- Developer Band Therapeutics; Medical University of Vienna
- Class Antithrombotics; Oligonucleotides; Polyethylene glycols; RNA; Vascular disorder therapies
- Mechanism of Action RNA modulators; Von Willebrand factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haemophilia A; Von Willebrand disease
- No development reported Arterial thrombosis; Atherosclerosis; Intracranial-Arteriosclerosis; Stroke
Most Recent Events
- 07 Dec 2024 Interim efficacy data from a phase II trial of Von Willebrand disease presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Arterial-thrombosis(Prevention) in USA (SC)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Austria (SC)